Storgate LLC Purchases New Holdings in Pfizer Inc. $PFE

Storgate LLC purchased a new stake in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 31,441 shares of the biopharmaceutical company’s stock, valued at approximately $783,000. Pfizer accounts for about 0.6% of Storgate LLC’s portfolio, making the stock its 23rd largest position.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after acquiring an additional 7,031,162 shares during the period. State Street Corp increased its position in Pfizer by 0.9% in the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock valued at $7,620,747,000 after acquiring an additional 2,786,098 shares during the period. Geode Capital Management LLC increased its position in Pfizer by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock valued at $3,235,642,000 after acquiring an additional 1,184,728 shares during the period. Norges Bank acquired a new position in Pfizer in the 4th quarter valued at about $1,830,986,000. Finally, Northern Trust Corp increased its position in Pfizer by 1.4% during the 3rd quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock worth $1,631,225,000 after purchasing an additional 869,175 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s new weight-loss data is being viewed as encouraging for its obesity franchise, potentially improving the competitive case for its pipeline and helping sentiment around future growth. Article Title
• Positive Sentiment: Pfizer’s expanded U.S. label for HYMPAVZI is adding to optimism around the hemophilia business by widening the addressable patient pool, which may support future specialty-drug sales. Article Title
• Positive Sentiment: RBC recently upgraded Pfizer to Sector Perform, saying the valuation has reset and the risk-reward profile looks more balanced ahead of pipeline catalysts. Article Title
• Positive Sentiment: Some recent articles argue Pfizer’s Seagen oncology platform and newly acquired obesity assets could help offset patent-expiry and post-COVID revenue pressure, supporting a long-term turnaround thesis. Article Title
• Neutral Sentiment: Analysts currently rate Pfizer around Hold on average, suggesting the market sees limited near-term upside until more pipeline and commercial execution proves out. Article Title
• Negative Sentiment: Bearish commentary continues to highlight Pfizer’s dividend yield as a sign of underlying concern about cash flow, debt, and the company’s ability to support both payouts and reinvestment. Article Title

Wall Street Analyst Weigh In

Several research firms have issued reports on PFE. Citigroup boosted their target price on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Bank of America dropped their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. BMO Capital Markets reiterated an “outperform” rating and set a $30.00 target price on shares of Pfizer in a research report on Monday, March 9th. Finally, Morgan Stanley boosted their target price on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $28.82.

Pfizer Stock Performance

NYSE PFE opened at $26.19 on Friday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The business’s 50 day moving average is $26.43 and its two-hundred day moving average is $26.32. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The stock has a market capitalization of $149.26 billion, a price-to-earnings ratio of 19.99 and a beta of 0.34.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts expect that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 12th. Stockholders of record on Friday, May 8th were paid a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. Pfizer’s payout ratio is 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.